The call for the de-listing of Chinese medicine injections is re-starting, and there are still drug safety issues

Recently, the Beijing Food and Drug Administration ordered China Resources 39 subsidiary Beijing China Resources Gaoke Natural Medicine Co., Ltdto stop production and stop selling its Shuheninginjection, and recall the products at riskChina Resources 39 aspects of this "secret", coupled with Shu Heining once belongs to the most abuseof aChinese medicineinjections, two factors superimposed, Shu Heining was discontinued to stop sales is
triggering a new round of market concerns about the safety andofchinese medicine injectionschinese medicine injectionre re-causing concern
Beijing Food and Drug Administration notice shows that Beijing China Resources Gaoke Natural Medicine Co., Ltdproduced Shuheinininjectionin the process of market supervision and inspection was found to existsafety risk, asked the company to recall the same batch of extractproduction production of Shuheinin injection and rectification During the rectification period, the production and sale of the hydro-heinin injection shall not continue, and the production of stock shuhein in the production of the injection products suspended from sale and use public information shows that Shu Hening has been detained "the most abused (beyond the scope of the instructions) of the Chinese medicine injection" hat China Medical Insurance Research Association, "2009-2011 National Urban Basic Medical Insurance Forresident Inpatient Sinada Analysis" report shows that Shu Heining injection sits first in the internal medicine ranking, the cost of use of 2.493 billion yuan, the number of diseases treated increased from 138 in 2010 to 154 in 2011, of which, the cost of super-adaptation certificate (beyond the scope of the use of instructions) occurred more than 1.2 billion yuan the State Administration of Food and Drug Administration issued a document in 2013, according to the results of the State Administration of Food and Drug Administration monitoring and evaluation, decided to revise the instructions for the injection of Shu heining, requiring the relevant pharmaceutical production enterprises to increase the warning language, specify ingested reaction
content, taboo content, content of precautions It is reported that the increased warning words are "the product of the adverse reaction
including anaphylactic shock, should be used in the medical institutions with rescue conditions, the user should be qualified to treat allergic shock and other serious allergic reactions or received training in anaphylactic shock rescue, after the use of allergic reactions or other serious adverse reactions must be immediately discontinued and timely treatment "
there are still problems of drug safety in fact, the Chinese medicine injection represented by the shuheinin injection has been a very controversial variety According to the Chinese Pharmacopoeia, "Chinese medicine injection" refers to a sterile solution, fluid or sterile powder with a dissolved substance derived from a monolith or compound extracted from a chinese medicine or natural medicine, guided by the theory of traditional Chinese medicine, which is guided by modern science and technology Chinese medicine injections caused so much controversy because of its frequent outbreaks of adverse reactions In the annual report on monitoring adverse drug reactions reported by the State Food and Drug Administration, Chinese medicine injections are often the "heavy hit areas" of serious adverse reactions Compared with the alarming reports of adverse reactions to Chinese medicine injections, the Chinese medicine injection industry has been developing at a high speed in recent years At the same time, there are repeated calls for the withdrawal of Chinese medicine injections, this shu hening incident, the call again 　　"Among all kinds of drug dosage forms and types, the technical requirements and quality standards of injections are the most stringent, the most important of which is that the injection must be clear ingredients, high purity of the drug, the efficacy of sufficient evidence, toxic side effects clear, which is the consensus of the international medical community, but also the most basic principles Zhou Chaofan, executive member of the editorial board of the Chinese Pharmacopoeia, believes that, from the current technology, Chinese medicine injections can not fully meet such requirements, there are still drug safety problems however, some experts pointed out that the attitude towards Chinese medicine injections to prevent two extremes, not because it has some problems on a stick to kill, but also can not protect china's Chinese medicine national populism and blindly protect To face up to the problem, find the cause of the problem, find out the targeted measures to improve the drug safety of Chinese medicine injections Zhao Binghui, reporter of the Southern Daily,